HPV16 Serologic Test for Therapy Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody tests for HPV16 positive carcinoma lack type specificity and are unable to detect relapse or metastasis effectively, as they measure total HPV L1 antibodies which remain stable over years and do not differentiate between HPV types, making them unsuitable for therapy control.
Innovation Solution
A serologic method using conformational epitope-specific HPV16 L1 capsid antibodies, where antibodies bind to HPV16 L1 capsid or capsomer structures not present in monomeric or denatured forms, allowing for the detection of antibody decreases post-treatment and increases indicating relapse or metastasis, utilizing labeled antibodies from the hybridoma cell line DSM ACC3306 for sensitive and type-specific therapy control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antibody tests measuring total HPV L1 antibodies are used, then the test can detect HPV antibodies in general, but the test lacks type specificity and cannot differentiate between HPV types
Solution Approach 1:
The patent applies local quality by using conformational epitopes specific to HPV16 L1 capsid structure. These epitopes are located at specific three-dimensional regions of the capsid that are unique to HPV16, allowing the antibody test to distinguish HPV16 from other HPV types while maintaining the ability to detect HPV antibodies in general.
Solution Approach 2:
The patent changes the parameter of antibody recognition from linear epitopes (present in monomeric and denatured forms) to conformational epitopes (present only in native capsid structure). This parameter change enables type-specific detection because conformational epitopes depend on the three-dimensional structure that is unique to each HPV type's capsid assembly.
2Duration of action of stationary object
If total HPV L1 antibody levels are measured, then the test can monitor antibody presence over time, but the levels remain stable over years and do not indicate relapse or metastasis
Solution Approach 1:
The patent uses conformational epitope-specific antibodies to detect changes in antibody levels that occur preliminary to clinical relapse or metastasis. By monitoring the dynamic changes in HPV16-specific antibody titers, the test can identify relapse early, before visible secondary tumors form, allowing for timely intervention.
3Measurement precision
If HPV16 specific E6 or E7 proteins are used for serologic detection, then type specific detection is achieved, but these protein antigens occur in all HPV types and are largely homologous
Solution Approach 1:
The patent segments the HPV L1 capsid into specific conformational epitopes that are unique to HPV16. By focusing on these discrete three-dimensional regions rather than using whole E6 or E7 proteins that are homologous across HPV types, the test achieves type-specific detection without cross-reactivity with other HPV types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of HPV16 positive carcinoma relapse or metastasis, allowing for timely intervention and increased chances of healing by tracking antibody levels over time, with a significant decrease observed within weeks post-treatment and a rebound indicating tumor regrowth.
Implementation Method 1
contacting a sample from a patient with an HPV16-positive carcinoma, having been administered an anti-cancer therapy, with a plurality of antigens comprising a conformational epitope of HPV16 L1 capsid or capsomer... under conditions at which antibodies present in the sample can bind to the antigens
Data Source
AI summary
A method for therapy control of HPV16 positive carcinoma, an antibody for use in the corresponding diagnostic method as well as a test for performing the method. In particular, a serologic method for monitoring the development of the amount of antibodies in samples, which were taken from a patient before and after the treatment of a HPV16 positive carcinoma over a predetermined period of time. In addition, an immunologic test in the form of a kit, with which the method can be performed.